Answers are grounded in this paper and cite their sources.
Testing for polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene is still a standard part of thrombophilia testing in many laboratories. However, it is clear that these polymorphisms are not risk factors for arterial or venous thrombosis and therefore should not be part of thrombophilia testing. Eliminating MTHFR from thrombophilia testing will reduce patient concerns and health care costs.
No takes yet. Share an insight, caveat, or question.
DeLoughery et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: